JP7633259B2 - ＴＧＦ－βＲＩＩ結合タンパク質 - Google Patents

ＴＧＦ－βＲＩＩ結合タンパク質 Download PDF

Info

Publication number
JP7633259B2
JP7633259B2 JP2022539245A JP2022539245A JP7633259B2 JP 7633259 B2 JP7633259 B2 JP 7633259B2 JP 2022539245 A JP2022539245 A JP 2022539245A JP 2022539245 A JP2022539245 A JP 2022539245A JP 7633259 B2 JP7633259 B2 JP 7633259B2
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
βrii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022539245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023508202A (ja
JP2023508202A5 (enExample
Inventor
マーク・スロスビー
リンス・クルースター
コルネリス・アドリアン・デ・クルーフ
Original Assignee
メルス ナムローゼ フェンノートシャップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルス ナムローゼ フェンノートシャップ filed Critical メルス ナムローゼ フェンノートシャップ
Publication of JP2023508202A publication Critical patent/JP2023508202A/ja
Priority to JP2023060823A priority Critical patent/JP7875406B2/ja
Publication of JP2023508202A5 publication Critical patent/JP2023508202A5/ja
Priority to JP2025018365A priority patent/JP2025083342A/ja
Application granted granted Critical
Publication of JP7633259B2 publication Critical patent/JP7633259B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022539245A 2019-12-24 2020-12-22 ＴＧＦ－βＲＩＩ結合タンパク質 Active JP7633259B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023060823A JP7875406B2 (ja) 2019-12-24 2023-04-04 ＴＧＦ－βＲＩＩ結合タンパク質
JP2025018365A JP2025083342A (ja) 2019-12-24 2025-02-06 ＴＧＦ－βＲＩＩ結合タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2024576 2019-12-24
NL2024576 2019-12-24
PCT/NL2020/050813 WO2021133167A1 (en) 2019-12-24 2020-12-22 Tgf-beta-rii binding proteins

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2023060823A Division JP7875406B2 (ja) 2019-12-24 2023-04-04 ＴＧＦ－βＲＩＩ結合タンパク質
JP2025018365A Division JP2025083342A (ja) 2019-12-24 2025-02-06 ＴＧＦ－βＲＩＩ結合タンパク質

Publications (3)

Publication Number Publication Date
JP2023508202A JP2023508202A (ja) 2023-03-01
JP2023508202A5 JP2023508202A5 (enExample) 2023-04-25
JP7633259B2 true JP7633259B2 (ja) 2025-02-19

Family

ID=69700252

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022539245A Active JP7633259B2 (ja) 2019-12-24 2020-12-22 ＴＧＦ－βＲＩＩ結合タンパク質
JP2023060823A Active JP7875406B2 (ja) 2019-12-24 2023-04-04 ＴＧＦ－βＲＩＩ結合タンパク質
JP2025018365A Pending JP2025083342A (ja) 2019-12-24 2025-02-06 ＴＧＦ－βＲＩＩ結合タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023060823A Active JP7875406B2 (ja) 2019-12-24 2023-04-04 ＴＧＦ－βＲＩＩ結合タンパク質
JP2025018365A Pending JP2025083342A (ja) 2019-12-24 2025-02-06 ＴＧＦ－βＲＩＩ結合タンパク質

Country Status (13)

Country Link
US (1) US12570747B2 (enExample)
EP (2) EP4269433A3 (enExample)
JP (3) JP7633259B2 (enExample)
KR (2) KR20220117267A (enExample)
CN (3) CN116199780A (enExample)
AR (2) AR120914A1 (enExample)
AU (4) AU2020412201B2 (enExample)
BR (1) BR112022012522A2 (enExample)
IL (2) IL294181A (enExample)
MX (2) MX2022007919A (enExample)
PH (1) PH12022551527A1 (enExample)
TW (2) TW202128747A (enExample)
WO (1) WO2021133167A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025083342A (ja) * 2019-12-24 2025-05-30 メルス ナムローゼ フェンノートシャップ ＴＧＦ－βＲＩＩ結合タンパク質

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024006018A (es) * 2021-11-19 2024-07-29 Merus Nv Unidades de union multiespecificas que comprenden los dominios de union a pd-1 y tgf-brii.
CN120731229A (zh) 2022-12-20 2025-09-30 美勒斯公司 FAP结合域以及结合FAP和TGF-βRII的双特异性结合部分

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
JP2012508170A (ja) 2008-11-07 2012-04-05 イムクローン・リミテッド・ライアビリティ・カンパニー 抗ｔｇｆベータ受容体ｉｉ抗体
JP2014504866A (ja) 2011-01-06 2014-02-27 グラクソ グループ リミテッド Ｔｇｆ−ベータ受容体ｉｉに結合するリガンド

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
EP3456191A1 (en) 2008-06-27 2019-03-20 Merus N.V. Antibody producing non-human mammals
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
JP2018527903A (ja) 2015-07-22 2018-09-27 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． Ｇｄｆ１１結合タンパク質およびその使用
TW201825519A (zh) * 2016-10-18 2018-07-16 美商美國禮來大藥廠 TGFβ受體II抗體
CA3094318A1 (en) 2018-03-30 2019-10-03 Merus N.V. Multivalent antibody
CN116199780A (zh) 2019-12-24 2023-06-02 美勒斯公司 TGF-β-RII结合蛋白质

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
JP2012508170A (ja) 2008-11-07 2012-04-05 イムクローン・リミテッド・ライアビリティ・カンパニー 抗ｔｇｆベータ受容体ｉｉ抗体
JP2014504866A (ja) 2011-01-06 2014-02-27 グラクソ グループ リミテッド Ｔｇｆ−ベータ受容体ｉｉに結合するリガンド

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025083342A (ja) * 2019-12-24 2025-05-30 メルス ナムローゼ フェンノートシャップ ＴＧＦ－βＲＩＩ結合タンパク質

Also Published As

Publication number Publication date
AR130991A2 (es) 2025-02-05
MX2024002182A (es) 2024-05-03
AR120914A1 (es) 2022-03-30
AU2020412201B2 (en) 2026-02-12
JP2025083342A (ja) 2025-05-30
KR20220117267A (ko) 2022-08-23
AU2023200779A1 (en) 2023-03-09
AU2023200779B2 (en) 2026-02-19
IL304317A (en) 2023-09-01
CN116199780A (zh) 2023-06-02
IL294181A (en) 2022-08-01
EP4081306A1 (en) 2022-11-02
US20250270331A1 (en) 2025-08-28
JP2023508202A (ja) 2023-03-01
WO2021133167A1 (en) 2021-07-01
EP4269433A3 (en) 2024-05-22
TW202417513A (zh) 2024-05-01
US12570747B2 (en) 2026-03-10
BR112022012522A2 (pt) 2022-09-06
AU2026203807A1 (en) 2026-06-04
CA3165605A1 (en) 2021-07-01
MX2022007919A (es) 2022-07-27
JP7875406B2 (ja) 2026-06-18
EP4269433A2 (en) 2023-11-01
PH12022551527A1 (en) 2024-01-29
CN115038497A (zh) 2022-09-09
KR20230145542A (ko) 2023-10-17
TW202128747A (zh) 2021-08-01
AU2026203599A1 (en) 2026-05-28
AU2020412201A1 (en) 2022-07-14
JP2023076596A (ja) 2023-06-01
CN116375869A (zh) 2023-07-04

Similar Documents

Publication Publication Date Title
TWI487712B (zh) 多重特異性抗體
US11525005B2 (en) Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
AU2023200779B2 (en) TGF-beta-RII binding proteins
JP2024530451A (ja) 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体及び応用
US10836833B2 (en) Cell engaging binding molecules
CA3207791A1 (en) Anti-cd112r antibody and use thereof
JP7352007B2 (ja) ヒト化抗ｖｅｇｆモノクローナル抗体
US20250188163A1 (en) Gprc5d antibodies with enhanced effector function and uses thereof
JP7538552B2 (ja) Ｌｉｆに特異的な結合分子及びその使用
CA3165605C (en) Tgf-beta-rii binding proteins
HK40094429A (en) Tgf-beta-rii binding proteins
KR20230004739A (ko) 인간화 항-인간 cd89 항체 및 이의 용도
EA051539B1 (ru) Белки, связывающие tgf-бета-rii
US20240301051A1 (en) Anti-cldn6 antibodies and methods of use
US20240301061A1 (en) Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
BR122023027661A2 (pt) Proteínas de ligação de tgf-beta-rii
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение
JP2026504439A (ja) 抗ｌｉｌｒｂ１抗体及び／又は抗ｌｉｌｒｂ２抗体、並びにその使用
HK40126767A (en) Anti-cd3 antibodies and uses thereof
WO2025214468A1 (zh) 抗il-15抗体以及其用途
HK40066221B (en) Humanized anti-vegf fab antibody fragment and use thereof
HK40066221A (en) Humanized anti-vegf fab antibody fragment and use thereof
BR112021003089A2 (pt) anticorpos biespecíficos anti-pd-l1/anti-lag3 e seus usos
EA045935B1 (ru) Антитела к cd3 и их применение

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240911

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250206

R150 Certificate of patent or registration of utility model

Ref document number: 7633259

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350